Reilly Herbert Faulkner Iii buys $4.7 Million stake in Henry Schein (HSIC)

Henry Schein (HSIC) : Reilly Herbert Faulkner Iii scooped up 106 additional shares in Henry Schein during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 27,403 shares of Henry Schein which is valued at $4.7 Million.Henry Schein makes up approximately 3.44% of Reilly Herbert Faulkner Iii’s portfolio.

Other Hedge Funds, Including , Cibc World Markets Corp reduced its stake in HSIC by selling 1,965 shares or 28.14% in the most recent quarter. The Hedge Fund company now holds 5,018 shares of HSIC which is valued at $862,945. Henry Schein makes up approx 0.03% of Cibc World Markets Corp’s portfolio.Shell Asset Management Co reduced its stake in HSIC by selling 2,590 shares or 4.63% in the most recent quarter. The Hedge Fund company now holds 53,347 shares of HSIC which is valued at $9.2 Million. Henry Schein makes up approx 0.22% of Shell Asset Management Co’s portfolio.California Public Employees Retirement System reduced its stake in HSIC by selling 200 shares or 0.08% in the most recent quarter. The Hedge Fund company now holds 263,525 shares of HSIC which is valued at $44.8 Million. Henry Schein makes up approx 0.07% of California Public Employees Retirement System’s portfolio.

Henry Schein closed down -1.21 points or -0.70% at $171.53 with 3,79,302 shares getting traded on Wednesday. Post opening the session at $172.86, the shares hit an intraday low of $171.24 and an intraday high of $173.32 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Henry Schein reported $1.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $1.39. The company had revenue of $2712.96 million for the quarter, compared to analysts expectations of $2667.28 million. The company’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.

Many Wall Street Analysts have commented on Henry Schein. Company shares were Reiterated by Barrington Research on May 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 188 from a previous price target of $182 .Henry Schein was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Barrington Research Upgraded Henry Schein on Mar 1, 2016 to ” Outperform”, Price Target of the shares are set at $182.

Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.

Leave a Reply

Henry Schein - Is it time to Sell?

Top Brokerage Firms are advising their investors on Henry Schein. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.